The Latest
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Generate Biomedicines’ $400 million offering is the biotech sector’s largest by total proceeds since Acelyrin’s $540 million IPO in May 2023.
Updated 18 hours ago -
AI-generated image by ProBio CDMO
Sponsored by ProBio CDMOSmall and mighty: single-domain antibodies pack a biological punch
VHH antibodies: they’re not just small, they're modular engineering platforms, capable of powerful biological activity. But with great power comes great challenges!
-
Getty Images
Startup launchesAtrium spins out of Avidity, aiming to target rare heart diseases with RNA
Four months after Avidity’s $12 billion buyout, Atrium debuted with $270 million in cash and plans to pick up its predecessor’s work in cardiovascular disease.
-
Getty Images
News roundupBoehringer drug approved in 44 days; BioMarin shelves Roctavian
Boehringer’s lung cancer medicine Hernexeos is the second “national priority” voucher winner to gain a speedy approval. Elsewhere, a landmark gene therapy was withdrawn and a Pfizer deal paid dividends.
-
Alamy
Bristol Myers says ADC licensed from China hits mark in aggressive breast cancer
The study result is the latest step forward for a drug Bristol could eventually pay more than $8 billion for and has spotlighted as important to its future growth.
-
Getty Images
Obesity drugsWith Vivtex deal, Novo gains a chance at better oral obesity drugs
The potentially $2.1 billion collaboration gives Novo access to technologies that are meant to help optimize the delivery of oral biologic medicines.
-
Courtesy of GSK
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
The deal hands GSK a drug it views as a potentially “best-in-class” therapy for blood pressure diseases like pulmonary arterial hypertension — the target of Merck’s fast-selling Winrevair.
-
Permission granted by Karissa Waddick
Alkermes’ Richard Pops to step down after three-decade run as CEO
One of biotech’s longest-tenured leaders, Pops steered Alkermes through several reinventions, the latest of which has made it a frontrunner in developing a new narcolepsy drug.
-
Elijah Nouvelage via Getty Images
Vaccines15 states sue HHS over changes to childhood vaccine schedule
The lawsuit seeks to reverse the abrupt overhaul of the U.S. immunization schedule as well as the federal government’s allegedly “unlawful” reformation of a key vaccine panel.
-
Kevin Frayer via Getty Images
China competitionDrugs from China are reshaping biotech. Track the licensing deals here.
At least 17 licensing deals involving China-discovered drugs — including three more this week — have been struck so far in 2026, surpassing last year’s record pace.
Updated Feb. 17, 2026 -
Alamy
Emerging biotechBreezeBio banks $60M to make more precise genetic medicines
The company has shed its former “GenEdit” name and strategy in favor of a plan to develop its own medicines, starting with a potential tolerance-inducing treatment for Type 1 diabetes.
-
Andrew Harnik via Getty Images
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
In his lengthy address Tuesday night, the president touted his efforts to make drugs and insurance more affordable but steered clear of hot-button issues like vaccine access and the GOP’s Medicaid cuts.
-
Courtesy of Novo Nordisk
Obesity drugsNovo, searching for a spark, spotlights new data for three-pronged obesity drug
Novo’s answer to a closely watched Lilly drug spurred roughly 20% weight loss after 24 weeks in a Phase 2 trial, results one of its executives claimed to be “differentiating.”
-
Permission granted by Slate Medicines
Startup launchesSlate starts up with $130M and a headache drug from China
The biotech is developing a drug aimed at a protein called PACAP, which has emerged as a potentially new way to prevent the onset of migraines.
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
GSK on Wednesday agreed to pay $950 million to acquire startup 35Bio, which is developing a treatment for different types of pulmonary hypertension.
Updated Feb. 25, 2026 -
Anna Moneymaker via Getty Images
Gene editingFDA fleshes out new roadmap for testing personalized therapies
At an event on Monday, the agency officially unveiled long-awaited draft guidance meant to help speed the development of bespoke treatments for extremely rare diseases.
-
Alamy
Merck to split cancer, specialty drug businesses in leadership shakeup
Ahead of the looming loss of Keytruda’s exclusivity, the company is creating a standalone, cancer-focused unit and a second business housing its other drugs and vaccines.
-
Permission granted by Gilead Sciences
Gilead to buy Arcellx in $7.8B wager on multiple myeloma cell therapy
The acquisition bolsters Gilead’s sputtering cell therapy business with a medication the company expects to become a “foundational treatment” for the blood cancer, its CEO said.
-
Getty Images
Vir climbs on Astellas deal, study results for ‘masked’ T cell engager
According to one analyst, the alliance and early data “validate” the oncology work of Vir, which was once purely an infectious disease specialist before changing course.
-
Getty Images
Novo to cut GLP-1 drug prices; Palvella soars on study data
Wegovy and Ozempic’s list prices will be reduced by as much as 50% effective next year. Elsewhere, Palvella’s market value surged past $1 billion while Pfizer nabbed rights to another obesity drug.
-
Andrew Harnik via Getty Images
FDA leaders say one pivotal trial, not two, should be ‘default’ for drug approvals
In a NEJM article, Commissioner Martin Makary and top deputy Vinay Prasad argued that the new policy should lower development costs and speed development without compromising agency standards.
-
Alamy
Obesity drugsNovo’s next-gen obesity shot fails to match Lilly drug in head-to-head study
Shares fell by more than 15% on results showing study participants receiving Novo’s CagriSema lost less weight than those who took Lilly’s Zepbound.
-
Kevin Dietsch via Getty Images
Trump sets fresh 10% global tariff — and plans to increase further
The new duties will go into effect Feb. 24, although the president has since signaled he will raise the rate to 15%.
Updated Feb. 21, 2026 -
Getty Images
AI is slashing jobs across industries. Will pharma be next?
Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.
-
Douglas Olivares via Getty Images
Roche gets FDA decision date on closely watched breast cancer drug
The agency could by late December approve a therapy that Roche sees as potentially becoming a new treatment standard for certain breast tumors.
-
Getty Images
News roundup
Madrigal sees a stock sell-off; ex-Novartis exec heads to Daiichi
Madrigal shares fell 11% despite again topping consensus sales numbers. Elsewhere, Daiichi Sankyo named a new research chief and J&J halted recruitment in an Alzheimer’s trial.
